» Articles » PMID: 23150673

C1q-induced LRP1B and GPR6 Proteins Expressed Early in Alzheimer Disease Mouse Models, Are Essential for the C1q-mediated Protection Against Amyloid-β Neurotoxicity

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2012 Nov 15
PMID 23150673
Citations 90
Authors
Affiliations
Soon will be listed here.
Abstract

Complement protein C1q is induced in the brain in response to a variety of neuronal injuries, including Alzheimer disease (AD), and blocks fibrillar amyloid-β (fAβ) neurotoxicity in vitro. Here, we show that C1q protects immature and mature primary neurons against fAβ toxicity, and we report for the first time that C1q prevents toxicity induced by oligomeric forms of amyloid-β (Aβ). Gene expression analysis reveals C1q-activated phosphorylated cAMP-response element-binding protein and AP-1, two transcription factors associated with neuronal survival and neurite outgrowth, and increased LRP1B and G protein-coupled receptor 6(GPR6) expression in fAβ-injured neurons. Silencing of cAMP-response element-binding protein, LRP1B or GPR6 expression inhibited C1q-mediated neuroprotection from fAβ-induced injury. In addition, C1q altered the association of oligomeric Aβ and fAβ with neurons. In vivo, increased hippocampal expression of C1q, LRP1B, and GPR6 is observed as early as 2 months of age in the 3 × Tg mouse model of AD, whereas no such induction of LRP1B and GPR6 was seen in C1q-deficient AD mice. In contrast, expression of C1r and C1s, proteases required to activate the classical complement pathway, and C3 showed a significant age-dependent increase only after 10-13 months of age when Aβ plaques start to accumulate in this AD model. Thus, our results identify pathways by which C1q, up-regulated in vivo early in response to injury without the coordinate induction of other complement components, can induce a program of gene expression that promotes neuroprotection and thus may provide protection against Aβ in preclinical stages of AD and other neurodegenerative processes.

Citing Articles

A systematic study of molecular targets of cannabidiol in Alzheimer's disease.

Patil N, Patil K, Jain M, Mohammed A, Yadav A, Dhanda P J Alzheimers Dis Rep. 2025; 8(1):1339-1360.

PMID: 40034365 PMC: 11863746. DOI: 10.1177/25424823241284464.


Genetic variants associated with age-related episodic memory decline implicate distinct memory pathologies.

Ali A, Milman S, Weiss E, Gao T, Napolioni V, Barzilai N Alzheimers Dement. 2024; 21(1):e14379.

PMID: 39559945 PMC: 11775541. DOI: 10.1002/alz.14379.


Therapeutic Targets in Innate Immunity to Tackle Alzheimer's Disease.

Serradas M, Ding Y, Martorell P, Kulinska I, Castro-Gomez S Cells. 2024; 13(17.

PMID: 39272998 PMC: 11394242. DOI: 10.3390/cells13171426.


C5aR1 antagonism suppresses inflammatory glial responses and alters cellular signaling in an Alzheimer's disease mouse model.

Schartz N, Liang H, Carvalho K, Chu S, Mendoza-Arvilla A, Petrisko T Nat Commun. 2024; 15(1):7028.

PMID: 39147742 PMC: 11327341. DOI: 10.1038/s41467-024-51163-6.


Beneficial versus Detrimental Effects of Complement-Microglial Interactions in Alzheimer's Disease.

Ayyubova G, Fazal N Brain Sci. 2024; 14(5).

PMID: 38790413 PMC: 11119363. DOI: 10.3390/brainsci14050434.


References
1.
Liu C, Li Y, Schwartz A, Bu G . The putative tumor suppressor LRP1B, a novel member of the low density lipoprotein (LDL) receptor family, exhibits both overlapping and distinct properties with the LDL receptor-related protein. J Biol Chem. 2001; 276(31):28889-96. DOI: 10.1074/jbc.M102727200. View

2.
Khoury M, Parker I, Aswad D . Acquisition of chemiluminescent signals from immunoblots with a digital single-lens reflex camera. Anal Biochem. 2009; 397(1):129-31. PMC: 2808431. DOI: 10.1016/j.ab.2009.09.041. View

3.
Kayed R, Head E, Sarsoza F, Saing T, Cotman C, Necula M . Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegener. 2007; 2:18. PMC: 2100048. DOI: 10.1186/1750-1326-2-18. View

4.
Webster S, OBarr S, Rogers J . Enhanced aggregation and beta structure of amyloid beta peptide after coincubation with C1q. J Neurosci Res. 1994; 39(4):448-56. DOI: 10.1002/jnr.490390412. View

5.
Tenner A, Lesavre P, Cooper N . Purification and radiolabeling of human C1q. J Immunol. 1981; 127(2):648-53. View